POSTERIOR REVERSIBL ENCEPHALOPATHY SYNDROME IN COVID 19 DISEASE: A RARE CASE

Yıl 2022, Cilt: 13 Sayı: 2, 43 - 46, 23.06.2022

Öztürk Taşkın , Ayşe Yılmaz , Veysel Garani Soylu , Ufuk Demir , Gizem Kurada

https://doi.org/10.33706/jemcr.1022869

Cited By: 1

Öz

Background: Covid-19 disease can have many neurological complications, posterior reversible encephalopathy being one of them.

Case Report: A 42-year-old female patient was admitted to the emergency department on the 4th day of PCR test positivity with decreased consciousness. Patient with a Glasgow coma score of 6 (E1M3V2). The patient's vital signs were stable and there was no abnormality in his laboratory. No pathology was found in the brain tomography to explain the loss of consciousness. In MRI evaluation, the patient was diagnosed with Posterior reversible encephalopathy syndrome (PRES) according to radiological and clinical information. The standard Covid -19 treatment added to the antiedema treatment was applied to the patient. Brain MRI was repeated four days later and previous MRI findings showed regression. The patient was discharged to the ward with stable neurological status on the 22nd day of hospitalization.
Conclusion: PRES is a rare but serious complication in Covid-19. Especially in the Covid-19 intensive care unit, intubation and sedation suppress the clinical picture, and the difficulty in getting patients on magnetic resonance imaging can complicate the diagnosis. Therefore, PRES should be kept in mind in the presence of neurological symptoms such as encephalitis, meningitis, encephalopathy and cerebrovascular disease.

Anahtar Kelimeler

Covid-19, Posterior reversible encephalopathy syndrome, Intensive Care Unit, neurology

Kaynakça

• REFERENCES 1. Coronavirüs hastalığı (COVID-19) Pandemisi. Cenevre: Dünya Sağlık Örgütü. 2020. https://www.who.int/emergencies/diseases/novel- coronavirus-2019 . 28.10.2021
• 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
• 3. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020;11(7):995-998. doi:10.1021/acschemneuro.0c00122
• 4. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. doi:10.1056/NEJM199602223340803
• 5. Floeter AE, Patel A, Tran M, et al. Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy. Clin Lymphoma Myeloma Leuk. 2017;17(4):225-230. doi:10.1016/j.clml.2016.12.004
• 6. Ringelstein EB, Knecht S. Cerebral small vessel diseases: manifestations in young women. Curr Opin Neurol. 2006;19(1):55-62. doi:10.1097/01.wco.0000200545.37539.4e
• 7. Franceschi AM, Ahmed O, Giliberto L, Castillo M. Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection. AJNR Am J Neuroradiol. 2020;41(7):1173-1176. doi:10.3174/ajnr.A6595
• 8. Yamaoka-Tojo M. Vascular Endothelial Glycocalyx Damage in COVID-19. Int J Mol Sci. 2020;21(24):9712. Published 2020 Dec 19. doi:10.3390/ijms21249712
• 9. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol. 2006;27(10):2179-2190.
• 10. Siegler JE, Heslin ME, Thau L, Smith A, Jovin TG. Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center. J Stroke Cerebrovasc Dis. 2020;29(8):104953. doi:10.1016/j.jstrokecerebrovasdis.2020.104953